Therapeutic Focus GeNeuro targets diseases linked to Human Endogenous Retroviruses, including multiple sclerosis, ALS and long-COVID, creating partnerships with pharma groups pursuing first-in-class neuroinflammatory and autoimmune therapies.

Pipeline Partners Core assets such as temelimab with ongoing MS and long-COVID exploration, GN-K01 in preclinical ALS, and the ProTEct-MS program offer opportunities for licensing, co-development, or investment with partners seeking biomarker-driven programs.

Strategic Financing European financing activity and credit arrangements signal investor interest and potential co-funding for clinical programs, supporting milestone-based deals and shared risk with partners.

European Footprint Geneuro's Geneva base and European listing present collaboration pathways with EU pharma, hospitals, and public programs, with potential to engage US partners for cross-border trials and regulatory alignment.

Evidence Ready Ongoing Phase 2 trials and preclinical programs provide data generation capabilities to support regulatory submissions, payer discussions, and late-stage collaboration or licensing opportunities.